Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  days prior to study Day  or who has not recovered (i.e., ? Grade  or at baseline) from adverse events due to a previously administered agent.

SAFETY RUN-IN: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent

RANDOMIZED PHASE II CLINICAL TRIAL: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent

Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or not recovered from adverse events due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy or radiation therapy within  weeks prior to registration, or who has not recovered (i.e., =< grade  or baseline) from adverse events (AEs) due to previously administered agents

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks of study Day  or not recovered from adverse events caused by a previously administered agent

Prior systemic anti-cancer therapy including investigational agent within  weeks prior to study Day  or not recovered from adverse events due to a previously administered agent

Prior chemotherapy within  weeks, targeted small molecule therapy or radiation therapy within  weeks prior to enrollment, or who has not recovered (i.e., ?Grade  at enrollment) from AEs due to a previously administered agent.

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to the first dose of MK- or has not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent

Has received any prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an investigational agent or device before the first dose of study treatment, or has not recovered from AEs due to previously administered agents

Chemotherapy, targeted small molecule therapy, radiotherapy, experimental agents, prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents, or biological cancer therapy (including monoclonal antibodies) within  days prior to the start of study drug, or not recovered (=< grade  or baseline) from adverse events due to a previously administered agent

Prior chemotherapy, targeted therapy, or radiation therapy =<  weeks prior to registration or who has not recovered (i.e. to =< grade  or baseline) from an adverse event due to the previously administered therapy

Prior chemotherapy or targeted small molecule therapy of the current sarcoma. In patients with locally recurrent disease, previous systemic chemotherapy of the primary tumor is allowed, as long as treatment was completed prior to study enrollment and patient has recovered (i.e., < grade  or at baseline) from any adverse events due to previously administered agents.

Has had prior chemotherapy, radiation, hormonal, monoclonal antibody (mAb) or targeted small molecule therapy, within  weeks prior to the first study procedure (apheresis); subjects who have not recovered to < grade  from an adverse event due to a previously administered agent are not eligible

Had within  weeks prior to the first dose of study treatment, received prior chemotherapy, targeted small molecule therapy, or radiation therapy, or who has not recovered from adverse events due to a previously administered agent or major surgery

Must have recovered (i.e., adverse event [AE] =< grade  or stable) from AEs due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or who has not recovered (i.e., ?Grade  or at baseline) from AEs due to a previously administered agent.

Chemotherapy, monoclonal antibody, targeted small molecule therapy, within  weeks prior to dose # or who has not recovered (i.e., =< grade  or at baseline) for adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study)

Prior chemotherapy or radiation therapy =<  weeks prior to registration or who has not recovered (i.e. to =< grade  or baseline) from an adverse event due to the previously administered therapy

Subjects must not have received chemotherapy or targeted small molecule therapy within  half-lives of the specific agent(s), or radiation therapy within  weeks prior to the first dose of study medication, and must have recovered (=< grade ) from adverse events related to a previously administered agent

Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to starting study treatment or not recovered from adverse events due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  days prior to study Day  or who has not recovered (i.e., ?Grade  or at baseline) from AEs due to a previously administered agent.

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy, abiraterone treatment, enzalutamide treatment, or radiation therapy within  weeks prior to first dose of study therapy or who has not recovered (ie, Grade ? or at baseline) from AEs due to a previously administered agent

Has not recovered (i.e., AE ? Grade  or at Baseline) from AEs due to a previously administered agent.

Has had prior anti-myeloma therapy within  weeks prior to study start and has not recovered (i.e., ? Grade  or at Baseline) from adverse events due to a previously administered agent

Has undergone prior allogeneic hematopoietic stem cell transplantation within the last  years, has received a live vaccine within  days of planned start of study therapy, has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day , received a monoclonal antibody within  weeks prior to study Day  or has not recovered from adverse events due to a previously administered agent

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to first dose of study drug, or has not recovered from adverse effects due to a previously-administered agent

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or has not recovered (i.e., ? Grade  or at baseline) from AEs due to a previously administered agent .

Has not recovered from adverse events to ? Grade  or prior treatment level due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or who has not recovered (i.e., ?Grade  or at baseline) from adverse events due to a previously administered agent.

Prior anti-cancer mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to first dose of study medication or not recovered from adverse events due to a previously administered agent

Prior mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or not recovered (i.e., ? Grade  or at baseline) from AEs due to a previously administered agent.

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or not recovered from adverse events due to a previously administered agent or surgery

Radiation therapy (or other non-systemic therapy) within  weeks prior to randomization or not fully recovered from adverse events due to a previously administered treatment

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or not recovered from AEs due to a previously administered agent

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks of study Day  or not recovered from adverse events due to a previously administered agent

Not recovered from AEs due to a previously administered therapy

Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks ( weeks for measurable sites of central nervous system [CNS] disease) prior to study Day  or not recovered from adverse events due to a previously administered agent

Chemotherapy administered for the diagnosis of seminoma:\r\n* Prior chemotherapy for a different cancer is allowed, provided therapy was completed more than twelve months from first fraction of proton therapy administered in this study and the participant has recovered to grade =<  toxicity related to agents previously administered

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent

Had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to Study Day  or who has not recovered from adverse events due to a previously administered agent or major surgery

Prior history of hypersensitivity to taxane or platinum therapy; if either agent was previously administered, the patient must have tolerated it well and have recovered from any adverse events

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent

Prior systemic anticancer therapy within  weeks prior to enrollment or who has not recovered (i.e. ? Grade  or baseline grade) from adverse events due to a previously administered agent

Has not recovered (e.g., to ? Grade  or to baseline) from AEs due to a previously administered therapy.

Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy including investigational agents within  weeks prior to study Day  or who has not recovered (i.e., ? Grade  or at baseline) from AEs due to a previously administered agent.